Glipizide - A review of the pharmacoeconomic implications of the extended-release formulation in Type 2 diabetes mellitus

Citation
Rh. Foster et Gl. Plosker, Glipizide - A review of the pharmacoeconomic implications of the extended-release formulation in Type 2 diabetes mellitus, PHARMACOECO, 18(3), 2000, pp. 289-306
Citations number
75
Categorie Soggetti
Pharmacology
Journal title
PHARMACOECONOMICS
ISSN journal
11707690 → ACNP
Volume
18
Issue
3
Year of publication
2000
Pages
289 - 306
Database
ISI
SICI code
1170-7690(200009)18:3<289:G-AROT>2.0.ZU;2-3
Abstract
Sources: Medical literature published in any language since 1983 on glipizi de, identified using AdisBase (a proprietary database of Adis International , Auckland, New Zealand) and Medline. Additional references were identified from the reference lists of published articles. Bibliographical informatio n, including contributory unpublished data, was also requested from the com pany developing the drug. Search strategy: AdisBase search terms were 'Glipizide' or 'Type-2-diabetes -mellitus' and ('health-economics' or 'pharmacoepidemiology' or 'prescribin g' or 'hospitalisation' or 'formularies' or 'drug-utilisation' or 'meta-ana lysis' or 'therapeutic-substitution' or 'epidemiology'), or 'Glipizide' and 'Type-2-diabetes-mellitus'. Medline search terms were 'Glipizide' or 'Type -2-diabetes-mellitus' and ('economics' or 'health-policy' or 'quality-of-li fe' or 'models-statistical' or 'health-planning' or 'epidemiology' or 'guid eline in pt' or 'practice-guidelines in pt'. Searches were last updated 01 August 2000. Selection: Economic analyses in patients with type 2 diabetes mellitus who received Glipizide Gastrointestinal Therapeutic System. Inclusion of studie s was based mainly on the methods section of the trials. Relevant backgroun d data on epidemiology and cost of illness are also included.